Q-omics provides the consensus-scored GGTLC1 profile across patient tissues and cancer cell-line models. GGTLC1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, GGTLC1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, GGTLC1 RNA expression shows 14,254 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KICH, and LSCC as cancer lineages where GGTLC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGTLC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGTLC1 survival associations across molecular data types. GGTLC1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGTLC1 RNA expression–survival associations across cancer types. High GGTLC1 expression shows unfavorable associations in LUSC, UVM and MESO, but favorable associations in LUAD, KIRC and KIRP. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for GGTLC1 RNA expression.
This table summarizes GGTLC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for GGTLC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGTLC1 shows lower tumor expression in KICH, LUSC, LUAD, THCA and KIRC and higher tumor expression in UCEC. The KICH box plot shows higher GGTLC1 RNA expression in normal versus tumor tissue (log2 FC = −0.671, t-test p < 0.001).
This table shows molecular features associated with GGTLC1 in patient tissues and cancer cell lines. In patient samples, GGTLC1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GGTLC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
